| |
Deciphera's kinase switch inhibitors
Distinguishing features
Controlling kinase shape- Switch inhibitors control kinase activity by regulating protein shape, mimicking how cellular kinases are naturally controlled.
New therapies in cancer- Oncogenic (cancer-causing) kinases are often mutated, such that control of kinase shape and activity is lost. Deciphera's approach restores control to such dysregulated kinases.
Solving the problems of drug resistance- Switch inhibitors retain potency against drug-resistant kinase mutations, including mutations in the gatekeeper region.
Control of kinase inhibitor selectivity profiles- Switch inhibitor strategies enable unprecedented selectivity profiles relative to other kinase inhibitor classes.
Switch inhibition of kinases is general- Deciphera has identified kinase switch inhibitors from all major kinase families, including kinases involved in metabolic diseases, inflammation, and cardiovascular deseases.
|
|
Development Programs
DCC-2036
Late-stage preclinical development
Phase 1 trials in CML scheduled for Q1 2009.
» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant, resistant to all marketed kinase inhibitors.
DCC-2157
Preclinical development
» Inhibitor of BCR-ABL and T315I BCR-ABL gatekeeper mutant, resistant to all marketed kinase inhibitors.
DP-3407/DP-3429
» Inhibitor primary mutant cKIT kinase and major secondary mutant forms including V654A, D816V, D816H, T670I
Discovery Programs
DP-3346
» Inhibitor of all RAF kinase isoforms, including V600E oncogenic mutant
DP-3590
» Inhibitor of cMET kinase
|
|
In the News
Eli Lilly and Company (NYSE:LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential oncology therapeutics.
The collaboration will apply Deciphera's phylomechnanics discovery platform, a unique, proprietary approach to kinase inhibitor design, together with Lilly's expertise in discovery, development and commercialization to pursue first-in-class drug candidates for a variety of cancers.
Laboratory space temporarily vacant at the University of Kansas will soon be put to good use in a new and innovative way. Effective November 1, 2008, it will be leased for an initial 18 months to a growing, Kansas-based, biosciences company in need of space to expand its operations.
Deciphera Pharmaceuticals LLC (Lawrence, Kansas) announces the appointment of Dr. James A. Bristol to its Board of Managers.
|
